// PROTOCOLS / longevity
▶ Longevity protocol
Longevity pages distinguish between measured healthspan practices, biomarker claims, public critiques, and low-confidence aspirational claims such as immortality by 2039.
Daily inputs, long-range targets, and explicit avoidances are separated into the same terminal panels as the BJ.WATCH reference. Source-aware summary only.
idxtimehabit
01 nightHBT Prioritize measured healthspan basics: exercise, sleep regularity, nutrition, risk-factor monitoring, and clinician-guided prevention.
concepts/biomarker-driven-longevity-protocols.md 02 dailyHBT Read biological-age and speed-of-aging numbers as tracked claims with source trails and critique links nearby.
raw/articles/bryan-johnson/years-biomarkers-limits-2026-04-20.md Long-term objectives
target 01 Separate durable healthspan practices from frontier enhancement, drug-stack, gene-therapy, and immortality narratives.concepts/biomarker-driven-longevity-protocols.md
target 02 Treat the September 2026 Eight Sleep biological-age model as a commercial measurement claim with a real but unreviewed preprint behind it. The post’s figures track BCG-FM (Kjaer et al., arXiv:2606.07692: 2.04M hours / 136,575 participants; 3.26-year MAE; diabetes 0.852, heart failure 0.822, hypertension 0.810, sleep apnea 0.792 AUROC), but the product is a membership feature co-developed with Johnson’s Immortals, its internal disease labels are self-reported, and it is not a diagnostic device by the post’s own words. Not a validated longevity measurement, a purchasing signal, or medical advice.https://x.com/bryan_johnson/status/2095675388810936586
target 03 Classify daily Tadalafil/Cialis and similar drug claims as hypothesis-generating prescription-intervention claims unless independent clinical evidence supports the exact longevity use case.raw/articles/bryan-johnson/x-twitter-daily-2026-06-13.md
target 04 Classify Immortals Rx GLP-1, SGLT2, peptide, and NAD+ listings as commercial platform expansion; do not treat off-label longevity positioning as proven outcome evidence.raw/articles/bryan-johnson/x-twitter-daily-2026-06-23.md
target 05 Classify the July 2026 six-option GLP-1 catalog as a more specific commercial listing, not validation of weight-loss or longevity efficacy, compounded-treatment safety, prescribing criteria, formulation status, or availability.raw/articles/bryan-johnson/x-twitter-daily-2026-07-23.md
target 06 Classify Johnson’s August 2026 Viagra-plus-statins cancer-spread post as a low-confidence, product-adjacent intervention claim. The post itself labels the study preclinical and human evidence observational, and its extension from sildenafil to tadalafil is not established treatment evidence.raw/articles/bryan-johnson/x-twitter-daily-2026-08-04.md
target 07 Classify sauna/HSP27 claims as mechanistic biomarker self-experimentation unless replicated and tied to clinically meaningful outcomes.raw/articles/bryan-johnson/x-twitter-daily-2026-06-17.md
target 08 Classify the July 2026 sauna checklist as an attributed expansion from N=1 biomarker testing into public protocol guidance; its frequency, heat-dose, fertility, microplastics, recovery, hydration, and environmental claims require independent evidence and safety context.raw/articles/bryan-johnson/x-twitter-daily-2026-07-24.md
target 09 Classify the Midjourney scanner essay as a measurement-modality argument; structural imaging may complement chemical and functional data, but the third-party device and routine-screening claims need validation.raw/articles/bryan-johnson/x-twitter-daily-2026-06-24.md
target 10 Classify Johnson’s June 2026 wearable reply as a relative-tracking claim: consistency can help trend detection, but it does not settle absolute accuracy or clinical validity.raw/articles/bryan-johnson/x-twitter-daily-2026-06-25.md
target 11 Classify the inherited-cancer DNA + RNA panel as early-risk surveillance framing: useful for understanding Johnson’s measurement stack, not evidence that broad genetic screening improves outcomes for every reader.raw/articles/bryan-johnson/x-twitter-daily-2026-06-26.md
target 12 Classify the July 2026 single-cell immune sequencing thread as an AIG diagnostic/readout extension, not as proof that Johnson has a validated antigen-specific therapy.raw/articles/bryan-johnson/x-twitter-daily-2026-07-04.md
target 13 Classify the July 2026 low-ferritin / Monoferric follow-up as self-reported diagnostic follow-through and a false-negative argument, not as generalized iron-infusion guidance.raw/articles/bryan-johnson/x-twitter-daily-2026-07-08.md
target 14 Classify the July 2026 AIG cure roadmap as a staged, investigational personal experiment; the “Bryan in a dish” ex-vivo model and candidate precision therapies are not established clinical outcomes.raw/articles/bryan-johnson/x-twitter-daily-2026-07-09.md
target 15 Classify the July 2026 Kate Tolo endometriosis workup as a female-health measurement case study: complementary tests can expose false negatives, but Johnson’s case narrative is not a validated general protocol or medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-07-10.md
target 16 Classify the July 2026 1,900-biomarker / 14.8M-data-point Kate Tolo announcement as measurement-scale ambition. It is a planned N=1 collection program, not completed or independently validated female-health evidence.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
target 17 Classify Johnson’s July 2026 disease-resolution/frontier-biotech pivot as strategic positioning. The disease and proposed research program are unspecified, so the announcement is not evidence of a cure or protocol change readers can act on.raw/articles/bryan-johnson/x-twitter-daily-2026-07-21.md
target 18 Classify Johnson’s July 2026 autologous iPSC “clone” post as speculative regenerative-biotech positioning. It supplies no cell-line characterization, cited trial, organ, delivery method, safety evidence, or outcome and is not evidence of a human clone or available treatment.raw/articles/bryan-johnson/x-twitter-daily-2026-07-22.md
target 19 Classify Immortals’ July 2026 disease-resolution infrastructure expansion as strategic frontier-biotech positioning. Naming iPSCs, organoids, deep cellular characterization, and personalized therapy development does not establish a clinically available platform or evidence of diagnosis, treatment, safety, cure, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-25.md
target 20 Classify the July 2026 operational Kate Tolo baseline as measurement-scale ambition and protocol operations. The 100-day N=1 plan is not completed or independently validated female-health evidence, and its sensitive-data methods and governance remain unpublished.raw/articles/bryan-johnson/x-twitter-daily-2026-07-26.md
target 21 Classify Johnson’s August 2026 brain-clearance post as an uncited, preclinical research lead. The source describes one intranasal gene therapy in mice but supplies no named paper, human evidence, translational safety data, Blueprint intervention, or clinical outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-08-14.md
target 22 Classify Johnson’s August 2026 mRNA–Keytruda post as third-party research commentary. He describes a tumor-fingerprint mRNA therapy paired with Keytruda in a first Phase 3 trial but names no trial, paper, sponsor, or data, so it is not a Blueprint intervention, an available treatment, or medical advice.https://x.com/bryan_johnson/status/2090212567235149828
target 23 Keep the Immortals rename and immortality search-trend narrative in the ideology/brand lane; it does not increase confidence in the 2039 forecast.raw/articles/bryan-johnson/x-twitter-daily-2026-06-20.md
target 24 Keep the June 2026 immortality manifesto and “Die Economy” frame in the ideology/forecast lane unless independent evidence supports the specific biological and AI claims.raw/articles/bryan-johnson/x-twitter-daily-2026-06-25.md
target 25 Keep critiques visible so biomarker improvements do not become unsupported longevity promises.raw/articles/bryan-johnson/years-biomarkers-limits-2026-04-20.md
Forbidden
FORBID: Do not render “immortality by 2039” as a realistic forecast or medical endpoint.concepts/immortality-by-2039.md
FORBID: Do not collapse Johnson’s ideology, Blueprint marketing, and independent evidence into one confidence level.concepts/biomarker-driven-longevity-protocols.md